Cargando…
Insignificant effects of loss of heterozygosity in HLA in the efficacy of immune checkpoint blockade treatment
BACKGROUND: It is assumed that loss of heterozygosity and allelic copy loss in HLA gene is associated with poor response rates in immune checkpoint inhibitor treatment. H-owever, the accurate extents or consistency in cancer types have not been explored. OBJECTIVE: The goal of this study is to inves...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Singapore
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8921140/ https://www.ncbi.nlm.nih.gov/pubmed/35107815 http://dx.doi.org/10.1007/s13258-021-01207-8 |
_version_ | 1784669273365413888 |
---|---|
author | Yang, Yohan Kim, Eunyoung Kim, Sangwoo |
author_facet | Yang, Yohan Kim, Eunyoung Kim, Sangwoo |
author_sort | Yang, Yohan |
collection | PubMed |
description | BACKGROUND: It is assumed that loss of heterozygosity and allelic copy loss in HLA gene is associated with poor response rates in immune checkpoint inhibitor treatment. H-owever, the accurate extents or consistency in cancer types have not been explored. OBJECTIVE: The goal of this study is to investigate quantitative relationship between HLA allelic copy loss and response rates to immune checkpoint inhibitors. Also, tumor microenvironment was computationally assessed in the tumors with HLA copy loss to provide potential mechanisms for the relationships. METHOD: A total of 282 whole exome sequencing data from three cohorts of patients who received immune checkpoint blockade immunotherapy were analyzed, including Anti-PDL1 treated in metastatic urothelial cancer (N = 216), anti-PD1 treated metastatic melanoma (N = 26), and anti-CTLA4 treated metastatic melanoma (N = 39). The LOHHLA algorithm was used to calculate allelic copy number loss at each HLA-A, -B, and -C locus, and further determine HLA allelic copy loss status. The HLA copy status and ICB response rates were analyzed for association using Fisher’s exact test. The CIBERSORT-absolute algorithm was then used to analyze the patient's immune environment, which represented loss of heterozygosity, using paired matched RNA sequencing data. RESULTS: Unlike the general expectation, HLA allelic copy loss was not significantly associated with the ICB responses. Moreover, the relationship showed a reversed relationship in HLA-A in the urothelial cancer (better ICB response in HLA copy loss). Regardless of the HLA copy status, the proportion of cytotoxic immune cells in the immune environment of patients was correlated with ICB response, which was higher in the loss of heterozygosity group in the urothelial cohort. CONCLUSION: Although the loss of heterozygosity in HLA was generally expected to be an inhibitory factor in the immune treatment response by causing T cell immune evasion, our analysis demonstrates no explicit relationships. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s13258-021-01207-8. |
format | Online Article Text |
id | pubmed-8921140 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer Singapore |
record_format | MEDLINE/PubMed |
spelling | pubmed-89211402022-03-17 Insignificant effects of loss of heterozygosity in HLA in the efficacy of immune checkpoint blockade treatment Yang, Yohan Kim, Eunyoung Kim, Sangwoo Genes Genomics Research Article BACKGROUND: It is assumed that loss of heterozygosity and allelic copy loss in HLA gene is associated with poor response rates in immune checkpoint inhibitor treatment. H-owever, the accurate extents or consistency in cancer types have not been explored. OBJECTIVE: The goal of this study is to investigate quantitative relationship between HLA allelic copy loss and response rates to immune checkpoint inhibitors. Also, tumor microenvironment was computationally assessed in the tumors with HLA copy loss to provide potential mechanisms for the relationships. METHOD: A total of 282 whole exome sequencing data from three cohorts of patients who received immune checkpoint blockade immunotherapy were analyzed, including Anti-PDL1 treated in metastatic urothelial cancer (N = 216), anti-PD1 treated metastatic melanoma (N = 26), and anti-CTLA4 treated metastatic melanoma (N = 39). The LOHHLA algorithm was used to calculate allelic copy number loss at each HLA-A, -B, and -C locus, and further determine HLA allelic copy loss status. The HLA copy status and ICB response rates were analyzed for association using Fisher’s exact test. The CIBERSORT-absolute algorithm was then used to analyze the patient's immune environment, which represented loss of heterozygosity, using paired matched RNA sequencing data. RESULTS: Unlike the general expectation, HLA allelic copy loss was not significantly associated with the ICB responses. Moreover, the relationship showed a reversed relationship in HLA-A in the urothelial cancer (better ICB response in HLA copy loss). Regardless of the HLA copy status, the proportion of cytotoxic immune cells in the immune environment of patients was correlated with ICB response, which was higher in the loss of heterozygosity group in the urothelial cohort. CONCLUSION: Although the loss of heterozygosity in HLA was generally expected to be an inhibitory factor in the immune treatment response by causing T cell immune evasion, our analysis demonstrates no explicit relationships. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s13258-021-01207-8. Springer Singapore 2022-02-02 2022 /pmc/articles/PMC8921140/ /pubmed/35107815 http://dx.doi.org/10.1007/s13258-021-01207-8 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Research Article Yang, Yohan Kim, Eunyoung Kim, Sangwoo Insignificant effects of loss of heterozygosity in HLA in the efficacy of immune checkpoint blockade treatment |
title | Insignificant effects of loss of heterozygosity in HLA in the efficacy of immune checkpoint blockade treatment |
title_full | Insignificant effects of loss of heterozygosity in HLA in the efficacy of immune checkpoint blockade treatment |
title_fullStr | Insignificant effects of loss of heterozygosity in HLA in the efficacy of immune checkpoint blockade treatment |
title_full_unstemmed | Insignificant effects of loss of heterozygosity in HLA in the efficacy of immune checkpoint blockade treatment |
title_short | Insignificant effects of loss of heterozygosity in HLA in the efficacy of immune checkpoint blockade treatment |
title_sort | insignificant effects of loss of heterozygosity in hla in the efficacy of immune checkpoint blockade treatment |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8921140/ https://www.ncbi.nlm.nih.gov/pubmed/35107815 http://dx.doi.org/10.1007/s13258-021-01207-8 |
work_keys_str_mv | AT yangyohan insignificanteffectsoflossofheterozygosityinhlaintheefficacyofimmunecheckpointblockadetreatment AT kimeunyoung insignificanteffectsoflossofheterozygosityinhlaintheefficacyofimmunecheckpointblockadetreatment AT kimsangwoo insignificanteffectsoflossofheterozygosityinhlaintheefficacyofimmunecheckpointblockadetreatment |